BRAF and differentiated thyroid carcinoma: Hargrave et al.’s phase I/II study of dabrafenib (a BRAF V600 inhibitor) in pediatric patients with relapsed/refractory BRAF V600 positive tumors (including HGG, LGG, LCH, melanoma, papillary thyroid carcinoma) demonstrated a 44% objective response rate (ORR) in the pLGG population with an 85% 1-yr PFS rate (115).